
Meritage Homes: A Building Stock For All Seasons
New home being built with wood plank, trusses and assorted supplies
I originally made Meritage Homes (MTH) a Long Idea in June 2020 and reiterated my bullish thesis on the stock many times since.
Meritage Homes, is steadily taking market share, building and delivering homes faster, all the while returning capital to shareholders through dividends and repurchases. Despite an uncertain housing outlook in the short-term, my thesis remains intact, and the stock remains undervalued.
In the latest housing supply update, Freddie Mac estimated that the U.S. housing market was undersupplied by 3.7 million units as of 3Q24. The shortage of homes is a key driver of decreased housing affordability in the country. Put simply, when supply doesn't increase enough to meet demand, prices (home and rent) rise.
As the 5th largest homebuilder in the U.S., Meritage Homes' products remain in strong demand, throughout all economic cycles, because everyone needs a place to live.
Meritage Homes is in an advantageous position even as housing prices and interest rates remain high. The average sales price of new houses sold in the U.S. sits ~$404k in March 2025, up from ~$332k in February 2020, just before the COVID-19 pandemic sent home prices soaring. Entry-level homes, in which Meritage specializes, present a more viable and affordable option for any potential homebuyer.
In fact, Meritage Homes' homes closed (finished homes delivered to the customer) grew from 7,709 in 2017 to 15,520 in the TTM ending 1Q25. In turn, the company's market share of U.S. new one family homes increased from 1.3% in 2017 to 2.3% in the TTM. See Figure 1.
Figure 1: Meritage Homes' Share of U.S. New One Family Homes Sold: 2017 – TTM
MTH Market Share 2017-TTM
In 1Q25, Meritage Homes recorded its second highest first quarter orders and closings in company history.
Meritage Homes' spec home strategy, which offers move-in ready homes available to close within 60 days, speeds up the buying process. Essentially, this strategy shortens the time between home sale and home closing, and it can help target incentives and promotions to specific market conditions. Of the homes closed in 1Q25, approximately 61% were sold within the same quarter, up from 48% in the prior year period.
The company also achieved a record backlog (homes sold but not yet delivered) conversion rate of 221% in 1Q25, up from the 138% in 1Q24. Backlog refers to homes under contract that are not yet closed.
It's important to note that the decrease in Meritage Homes' backlog is not due to a decrease in demand, but rather due to a strategic pivot to shorten the sales cycle and sell homes later in the construction cycle.
When combining the number of homes in backlog and spec homes in inventory in 1Q25, Meritage has ~5 month supply, which is within the company's preferred range of 4-6 month supply.
Figure 2: Meritage Homes' Total Specs & Ending Backlog: 1Q24 – 1Q25
MTH Inventory 1Q24-1Q25
Meritage Homes' fundamentals have been improving over the years. The company has grown revenue and net operating profit after-tax (NOPAT) by 11% and 17% respectively from 2014 through the TTM ended 1Q25. The company's NOPAT margin improved from 7% in 2014 to 11% in the TTM, while invested capital turns fell from 1.5 to 1.2 over the same time. Rising NOPAT margins are enough to offset falling invested capital turns and drive Meritage Homes' return on invested capital (ROIC) from 10% in 2014 to 13% in the TTM.
Additionally, the company's Core Earnings, a proven superior earnings measure that excludes unusual gains/losses, grew 17% compounded annually from 2014 through the TTM ended 1Q25. See Figure 3.
While below 2022 highs, Meritage Homes' TTM ended 1Q25 Core Earnings are still higher than any annual period between 1998-2020.
Figure 3: Meritage Homes' Revenue and Core Earnings: 2014 – TTM
MTH Core Earnings and Revenue 2014-TTM
Meritage Homes started paying dividends at the beginning of 2023. Since then, Meritage Homes paid $179 million (4% of market cap) in cumulative dividends and increased its quarterly dividend from $0.14/share in 1Q23 to $0.43/share in 1Q25. The company's current dividend, when annualized, provides a 2.5% dividend yield.
Though Meritage Homes started paying dividends relatively recently, it's been returning capital to shareholders via share buybacks for much longer. From 2019 through 1Q25, the company repurchased shares worth $486 million (10% of market cap).
Since February 2019, Meritage Homes' Board of Directors has authorized the repurchase shares worth up to $750 million, with no specified expiration date. At the end of 1Q25, the company remains authorized to repurchase shares worth up to $264 million. Should the company repurchase shares at its TTM (ending 1Q25) rate, it would repurchase $115 million of shares over the next twelve months, which equals 2.3% of the current market cap.
When combined, the dividend and share repurchase yield could reach 4.8%.
Meritage Homes generates strong free cash flow (FCF) that covers both its share repurchases and regular dividend payments.
From 2019 through 1Q25, Meritage Homes generated $1.1 billion (26% of enterprise value) in FCF while returning $665 million over the same time ($179 million in dividends and $486 million in repurchases).
I like companies that choose to return capital to shareholders instead of spending it on costly executive bonuses or acquisitions that rarely drive shareholder value creation. See Figure 4.
Figure 4: Meritage Homes' Cumulative FCF Since 2019
MTH Cumulative Free Cash Flow 2019-1Q25
Mortgage rates have risen significantly from the record lows of 2021, when the 30-year fixed rate mortgage (FRM) was around 2.2% and the 15-year FRM was around 2.7%.
In May of 2025, Freddie Mac estimates that the average 30-year FRM sits at 6.8% and the average 15-year FRM sits at 5.9% in May 2025. See Figure 5.
High mortgage rates make purchasing a home more expensive and present a headwind to all builders.
Unfortunately, the easiest solution to aid consumers during times of high interest rates is to offer incentives and rate-buydowns, which create a drag on profitability.
Figure 5: 30- and 15-Year Fixed Rate Mortgage: May 2020 – May 2025
Mortgage Rates Past Five Years
In the 1Q25 earnings call, Meritage Homes' management noted that they don't yet know to what degree tariff-related cost increases will impact margins the remainder of the year.
However, management also noted that 'the current status quo of no tariffs on lumber should get us most of our expected 2025 closings completed at current market lumber prices.'
The company also intends to 'leverage its bargaining power with national vendors' given its large scale, limited floor plans, and high level of product visibility.
Due to the high interest and mortgage rates, many homebuilders have increased incentives and rate buydowns, which negatively impact margins.
Meritage Homes' average selling price (ASP) on home closings, home orders, and home backlogs fell 6%, 2%, and 1% YoY in 1Q25, respectively. Management noted that this decline was driven by 'increased utilization of financial incentives'. We can see the impact of these incentives in Meritage Homes' NOPAT margin, which fell from 12% in 1Q24 to 8.6% in 1Q25. In the company's 1Q25 earnings call, management noted: 'we anticipate the using of pricing incentives to remain elevated for the near future.'
The good news is that the impact of lower margins, and any general housing downturn, are already more than priced into MTH at its current price. Details below.
At its current price of $67/share, MTH has a price-to-economic book value (PEBV) ratio of 0.7. This ratio means the market expects the company's profits to permanently fall 30% from current levels. For context, Meritage Homes has grown NOPAT by 21% compounded annually over the last five years and 17% compounded annually over the last ten years. Perhaps even more impressive, the company has grown NOPAT 9% compounded annually over the past two decades.
Below, I use my reverse discounted cash flow (DCF) model to analyze expectations for different stock price scenarios for MTH.
In the first scenario, I quantify the expectations baked into the current price. If I assume:
the stock is worth $68/share today – nearly equal to the current stock price. In this scenario, Meritage Homes' NOPAT falls 5% compounded annually from 2025 – 2034. In this scenario, Meritage Homes' NOPAT would equal $471 million in 2034, or 32% below its TTM NOPAT.
If I instead assume:
the stock is worth $97/share today – a 45% upside to the current price. In this scenario, Meritage Homes' NOPAT would fall <1% compounded annually through 2034.
Should the company's NOPAT grow more in line with historical levels, the stock has even more upside. Furthermore, I think companies with long track records of profit growth deserve premium stock valuations, especially in a market filled with so many underperforming companies.
Figure 6 compares Meritage Homes' historical NOPAT to the NOPAT implied in each of the above scenarios.
Figure 6: Meritage Homes' Historical and Implied NOPAT: DCF Valuation Scenarios
MTH DCF Implied NOPAT
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Bloomberg
20 minutes ago
- Bloomberg
White House Prepares to Ease Rules for Big Banks, Politico Says
The Trump administration is preparing to ease rules imposed on the largest US banks following the 2008 financial crisis, Politico said, citing people with knowledge of the discussions. Regulators are close to completing a proposal that would reduce the size of the capital cushion that the biggest lenders must maintain to absorb potential losses and remain solvent in periods of economic stress, Politico reported Saturday.


CNN
24 minutes ago
- CNN
Smerconish Commentary: I'm Not Thrilled That Elon Musk is Out - Smerconish on CNN - Podcast on CNN Audio
Smerconish Commentary: I'm Not Thrilled That Elon Musk is Out Smerconish on CNN 44 mins Michael Smerconish delves into why he's willing to give Musk and President Trump some credit for sparking a conversation about waste, fraud and abuse. Plus, Michael Smerconish speaks with entrepreneur and investor Kevin O'Leary about Elon Musk's influence on U.S. industry and politics, the future of Tesla, and DOGE.


New York Times
34 minutes ago
- New York Times
Yordan Alvarez's ‘small' hand fracture adds another chapter to Astros' ambiguous medical history
HOUSTON — A month into an injured list stint for 'inflammation,' a small fracture has been discovered in Yordan Alvarez's right hand, sidelining the Houston Astros slugger for the foreseeable future while inviting further scrutiny on a medical staff struggling to get players back onto the field. Alvarez underwent imaging on Friday evening that revealed a 'small' fracture near the fourth metacarpal, general manager Dana Brown said on Saturday. The fracture is '60 percent healed,' according to Brown, who still hopes Alvarez can return 'in the near future.' Advertisement Alvarez has not appeared in a major-league game since May 2. On Saturday, the three-time All-Star acknowledged the injury occurred in a game prior to that date, but Alvarez attempted to play through it 'because I've played before with pain in my hand.' 'I didn't think it was going to be something big,' Alvarez added through an interpreter. 'But I think the fact that I kept playing caused my hand to stress more and caused the small fracture.' The team first described Alvarez's injury as a muscle strain on the top of his right hand. According to Brown, initial imaging taken on May 6 showed inflammation and fluid around the area. After three weeks of rest and ambiguous updates — always with positive undertones — team officials hoped Alvarez could return during this weekend's series against the Tampa Bay Rays. Two minor-league pitchers flew in from Florida on Friday morning to throw live batting practice against Alvarez at Daikin Park. Alvarez hit one home run into the right field seats and stung a few other line drives, but still felt pain in his right hand. Additional imaging ensued on Friday evening, which revealed the fracture. 'It doesn't surprise me that it was fractured,' Alvarez said. 'I knew there was something there on my first MRI with the muscle strain, but that's what I was dealing with. Time passed and it was supposed to get better, but it wasn't like that. I knew I couldn't go out there and support three or four games out there.' Both Brown and Alvarez said the Astros only took two images of Alvarez's hand: the one on May 6 and another on Friday evening. It's unclear why additional imaging wasn't ordered once Alvarez's inflammation subsided. Asked whether Friday's imaging came with Astros' doctors or an external physician, Alvarez replied, 'Both.' Brown acknowledged that Alvarez received a 'second opinion through him and his agent.' Alvarez's agent, Dan Lozano of MVP Sports Group, declined comment on Saturday. 'That's normal in baseball,' Brown said. 'There's a lot of guys that do that and we're not opposed to it. The beauty is our doctors will always communicate with the doctor (who gives) the second opinion and we'll work through it.' Advertisement Nowhere in Brown's team-written biography does it describe any medical education in his past, yet he sat atop a bench on Saturday afternoon attempting to explain how a $2.8 billion entity has now twice failed to discover a fracture in one of its franchise players. Last season, after insisting for almost three months that outfielder Kyle Tucker suffered a 'shin contusion,' the club acknowledged he suffered a fracture, but only after The Athletic prepared to report the story, citing multiple league sources. No two injuries are identical, but the parallel between Tucker and Alvarez's predicaments is difficult to ignore. Understanding how damaging the public perception can be is crucial, too. Players needing months to recover from fractures is understandable to a fan base. Needing that for a contusion or inflammation is more difficult to digest. The Astros continue to refuse all interview requests for head trainer Jeremiah Randall, claiming the sport's collective bargaining agreement prevents it. Still, the Pittsburgh Pirates, Minnesota Twins and Athletics are among teams that make their medical staffs available in either informal or on-the-record settings. The Detroit Tigers issue a formal injury report twice a week. On Saturday, Houston opted for its head of baseball operations to deliver a radiology lesson. 'I think part of the problem is twofold: You don't see the calcium or callus buildup until five weeks or so, and that's part of the problem,' Brown said. 'When you do these imagings and you have so much fluid and inflammation, it is very, very difficult to diagnose it. Even with multiple opinions, it's very difficult to see.' Both Brown and Alvarez acknowledged that swinging a bat within the past week may have exacerbated the injury, inviting wonder why Alvarez did so in the first place. Advertisement 'I was in agreement with that plan, but I knew something wasn't right,' Alvarez said on Saturday. 'But there wasn't anything more to show after the first MRI. When I first hit off the pitchers yesterday, I knew I wasn't going to be able to play three or four games straight and that's when we decided to do again the MRI.' Three years ago, former general manager James Click called into question the team's 'return to play procedure' after admitting Jake Meyers rushed back from a shoulder injury. Click promised a review, but got fired before it could be conducted. Perhaps it would behoove Brown to begin one of his own. He already acknowledged rushing pitcher J.P. France back from a shoulder injury last spring. Luis Garcia still hasn't appeared in a major-league game since undergoing Tommy John surgery in May 2023. Lance McCullers Jr. had several setbacks while recovering from flexor tendon surgery. Asked if he is concerned about how Houston's medical staff has handled his injury, Alvarez said he is not. 'Because maybe I should have said something before that I wanted another study,' Alvarez said through an interpreter. 'But I didn't do it because that was the first thing that came out. It got to the point where I wanted to do another study and that's what we did.' As a result of it, Alvarez will not swing a bat for the foreseeable future. Neither Alvarez nor Brown wanted to put a timeline on his return, though doing so would've accomplished little. Gone is any benefit of the doubt — or believability — in anything this team reveals about its injured players. 'Just let it heal completely and he'll be back,' Brown said.